Blood cancers such as leukemia are caused by genetic changes in the blood-forming stem cells of the bone marrow. Scientists ...

The IAEA and St. Jude Children’s Research Hospital have begun to develop new training curricula to upscale global capacity in paediatric cancer care by helping to close knowledge gaps around the world ...

Financial success will permit smart monetary investments today. There is no scope for debates and clashes in the relationship ...

To meet rising demand, developers of precision radiopharmaceutical therapies must overcome challenges in global isotope ...

Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an ...

Targeted therapies, guided by molecular testing, offer significant benefits, including fewer side effects and personalization ...

FDA approves Poherdy, the first interchangeable biosimilar for Perjeta, enhancing competition in HER2-positive breast cancer ...

Since the development of immune checkpoint inhibitors, very few advances have been made in the field of solid oncology therapeutics. This is due to the ...

OBI-902, targeting TROP2, gains FDA orphan drug status for cholangiocarcinoma, a rare cancer with poor prognosis and limited treatments. Orphan drug designation provides benefits like tax credits and ...

The Princess of Wales gave her first speech since her cancer diagnosis at a major event today - where she also revealed a ...

The FDA's fast track designation aims to expedite ITM-94's development for diagnosing clear cell renal cell carcinoma. The ...

The Princess of Wales stopped by the Future Workforce Summit in London to discuss her Royal Foundation’s Business Taskforce ...